EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany

Antje Mevius, Lars Jöres, Jutta Biskup, Tanja Heidbrede, Milada Mahic, Thomas Wilke, Ulf Maywald, Sophie Lehnerer, Andreas Meisel

Neuromuscular Disorders · 2023

DOI: 10.1016/j.nmd.2023.02.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuromuscular Disorders, 2023. Verfasst von Antje Mevius und 8 weiteren Autor:innen. Beteiligte Einrichtung: Ingress-health HWM GmbH, Alter Holzhafen 19, Wismar 23966, Germany. Electronic address: antje.mevius@ipam-wismar.de. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myasthenia gravis (MG) is a rare, chronic autoimmune disease with symptoms of fluctuating muscular weakness and fatigability. The aim of this retrospective cohort study was to estimate the prevalence and incidence of MG in Germany, and to understand the burden of disease and treatment patterns, based on anonymized German claims data. Two patient samples were identified: (1) incident MG patients with newly onset disease between 2015 and 2019, and (2) prevalent MG patients in 2019. In total, 775 incident MG patients with a mean age of 66.9 years; and 1,247 prevalent MG patients with a mean age of 68.6 years were included. The prevalence for Germany was estimated to be 39.3/100,000 on 31/12/2019; the incidence in 2019 was 4.6 cases/100,000 persons. The 12-month mortality was 5.7. For 31.5% of the incident patients, no MG treatment was observed in the first year after the index date. Of all incident patients, 29.9% experienced an exacerbation, and 6.7% a myasthenic crisis during the observation. Our study indicates that a substantial proportion of MG patients remains untreated. Many MG patients still experience exacerbations / MG crises. MG seems to be associated with an excess mortality in comparison to the general non-MG population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisHumansAgedRetrospective StudiesGermanyIncidencePrevalence

Stichwörter der Autor:innen

Burden of diseaseIncidenceMyasthenia gravisPrevalenceTreatment

Autor:innen und Institutionen

  • Ingress-health HWM GmbH, Alter Holzhafen 19, Wismar 23966, Germany. Electronic address: antje.mevius@ipam-wismar.de.
  • UCB Pharma, Alfred-Nobel-Str. 10,Monheim 40789, Germany.
  • UCB Pharma, 216 Bath Rd, Slough SL1 3WE, UK.
  • IPAM e.V., University of Wismar, Alter Holzhafen 19, Wismar 23966, Germany.
  • AOK PLUS, Sternplatz 7, Dresden 01067, Germany.
  • Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charitéplatz 1, Berlin 10117, Germany; Departme…

Zitieren

APA

Mevius, A., Jöres, L., Biskup, J., Heidbrede, T., Mahic, M., Wilke, T., Maywald, U., Lehnerer, S., & Meisel, A. (2023). Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscular Disorders. https://doi.org/10.1016/j.nmd.2023.02.002

Vancouver

Mevius A, Jöres L, Biskup J, Heidbrede T, Mahic M, Wilke T, et al. Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscular Disorders. 2023. doi:10.1016/j.nmd.2023.02.002

BibTeX
@article{Mevius2023,
  author = {Mevius, Antje and Jöres, Lars and Biskup, Jutta and Heidbrede, Tanja and Mahic, Milada and Wilke, Thomas and Maywald, Ulf and Lehnerer, Sophie and Meisel, Andreas},
  title = {Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany},
  journal = {Neuromuscular Disorders},
  year = {2023},
  doi = {10.1016/j.nmd.2023.02.002}
}
Kostenlos starten →